CN104198721B - 一种高尔基体蛋白73(gp73)抗原硅基磁珠结合物的制备及应用 - Google Patents
一种高尔基体蛋白73(gp73)抗原硅基磁珠结合物的制备及应用 Download PDFInfo
- Publication number
- CN104198721B CN104198721B CN201410360560.8A CN201410360560A CN104198721B CN 104198721 B CN104198721 B CN 104198721B CN 201410360560 A CN201410360560 A CN 201410360560A CN 104198721 B CN104198721 B CN 104198721B
- Authority
- CN
- China
- Prior art keywords
- silica
- magnetic bead
- solution
- antigen
- based magnetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 234
- 239000011324 bead Substances 0.000 title claims abstract description 147
- 239000000377 silicon dioxide Substances 0.000 title claims abstract description 118
- 239000000427 antigen Substances 0.000 title claims abstract description 65
- 102000036639 antigens Human genes 0.000 title claims abstract description 65
- 108091007433 antigens Proteins 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 102100021184 Golgi membrane protein 1 Human genes 0.000 title abstract description 14
- 101001040742 Homo sapiens Golgi membrane protein 1 Proteins 0.000 title abstract description 13
- 239000012224 working solution Substances 0.000 claims abstract description 44
- 238000001514 detection method Methods 0.000 claims abstract description 31
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 23
- 239000003513 alkali Substances 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 239000000758 substrate Substances 0.000 claims abstract description 15
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims abstract description 10
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims abstract description 10
- 238000004140 cleaning Methods 0.000 claims abstract description 10
- 239000012530 fluid Substances 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 74
- 238000006243 chemical reaction Methods 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 39
- 239000006249 magnetic particle Substances 0.000 claims description 39
- 239000008213 purified water Substances 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- 239000007853 buffer solution Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 239000006228 supernatant Substances 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 19
- 239000007983 Tris buffer Substances 0.000 claims description 17
- 239000002244 precipitate Substances 0.000 claims description 17
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 13
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 12
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 238000004020 luminiscence type Methods 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims description 9
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims description 9
- 102100031013 Transgelin Human genes 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 229940056319 ferrosoferric oxide Drugs 0.000 claims description 7
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 7
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 claims description 6
- 230000009514 concussion Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- XYIPYISRNJUPBA-UHFFFAOYSA-N [3-(3'-methoxyspiro[adamantane-2,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC(C3)CC2C4)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 XYIPYISRNJUPBA-UHFFFAOYSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 4
- 230000003139 buffering effect Effects 0.000 claims 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 150000001805 chlorine compounds Chemical class 0.000 claims 1
- CWAFVXWRGIEBPL-UHFFFAOYSA-N ethoxysilane Chemical compound CCO[SiH3] CWAFVXWRGIEBPL-UHFFFAOYSA-N 0.000 claims 1
- 210000002288 golgi apparatus Anatomy 0.000 claims 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical group O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 206010073069 Hepatic cancer Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 description 14
- 208000014018 liver neoplasm Diseases 0.000 description 14
- 230000035945 sensitivity Effects 0.000 description 8
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 6
- 239000006148 magnetic separator Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 239000003547 immunosorbent Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 101800001271 Surface protein Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- HZZDXVXOETXUEY-UHFFFAOYSA-N CC.[Na].[Na] Chemical compound CC.[Na].[Na] HZZDXVXOETXUEY-UHFFFAOYSA-N 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108050005430 Golgi membrane protein 1 Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013456 study Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- LFQCEHFDDXELDD-UHFFFAOYSA-N tetramethyl orthosilicate Chemical compound CO[Si](OC)(OC)OC LFQCEHFDDXELDD-UHFFFAOYSA-N 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410360560.8A CN104198721B (zh) | 2014-07-28 | 2014-07-28 | 一种高尔基体蛋白73(gp73)抗原硅基磁珠结合物的制备及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410360560.8A CN104198721B (zh) | 2014-07-28 | 2014-07-28 | 一种高尔基体蛋白73(gp73)抗原硅基磁珠结合物的制备及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104198721A CN104198721A (zh) | 2014-12-10 |
CN104198721B true CN104198721B (zh) | 2016-10-05 |
Family
ID=52084040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410360560.8A Active CN104198721B (zh) | 2014-07-28 | 2014-07-28 | 一种高尔基体蛋白73(gp73)抗原硅基磁珠结合物的制备及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104198721B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106226522A (zh) * | 2016-07-04 | 2016-12-14 | 福建广生堂药业股份有限公司 | 一种高尔基体蛋白73的检测方法、检测试剂和检测试剂盒 |
CN106568943A (zh) * | 2016-11-22 | 2017-04-19 | 百奥森(江苏)食品安全科技有限公司 | 一种食品中莱克多巴胺的检测试剂盒 |
CN107014997A (zh) * | 2017-03-28 | 2017-08-04 | 马杰 | 用于检测血清中高尔基糖蛋白73的抗体及试剂盒 |
CN107236045A (zh) * | 2017-05-08 | 2017-10-10 | 中国人民解放军第二军医大学 | 一种抗m6A单克隆抗体的制备方法 |
CN112255406B (zh) * | 2020-09-29 | 2023-04-14 | 北京利德曼生化股份有限公司 | 测定人体高尔基体蛋白含量的磁微粒化学发光检测试剂盒 |
CN113295866A (zh) * | 2021-04-26 | 2021-08-24 | 深圳市龙华区中心医院 | Upⅱ抗原和upⅱ抗体联合在制备检测膀胱癌的产品中的应用 |
CN113533734A (zh) * | 2021-07-22 | 2021-10-22 | 泰州泽成生物技术有限公司 | 一种磁微粒化学发光法检测高尔基体蛋白73的试剂盒及制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19621133A1 (de) * | 1996-05-24 | 1997-11-27 | Boehringer Mannheim Gmbh | Bestimmungsverfahren mit oligomerisierten Rezeptoren |
CN102495215B (zh) * | 2011-12-06 | 2014-01-22 | 任庆远 | 一种定量检测肿瘤坏死因子α的试剂盒 |
CN103499692B (zh) * | 2013-09-26 | 2015-10-14 | 江苏福隆生物技术有限公司 | 高尔基体蛋白gp73定量测定试剂盒及其检测方法 |
CN103903827B (zh) * | 2014-03-20 | 2018-01-23 | 哈尔滨益材新材料有限公司 | 一种磁性二氧化硅复合微球的制备方法及其应用 |
-
2014
- 2014-07-28 CN CN201410360560.8A patent/CN104198721B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104198721A (zh) | 2014-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104198721B (zh) | 一种高尔基体蛋白73(gp73)抗原硅基磁珠结合物的制备及应用 | |
CN105548565B (zh) | 一种用于检测克氏锥虫抗体的试剂盒及其制备和应用 | |
CN107543932A (zh) | 一种降钙素的磁微粒化学发光检测试剂盒及制备方法 | |
CN105785043B (zh) | 用于定量检测afp‑l3%的试剂盒 | |
Hong et al. | Detection of two different influenza A viruses using a nitrocellulose membrane and a magnetic biosensor | |
CN107831163A (zh) | 一种甲状腺球蛋白的化学发光检测试剂盒及其制备方法 | |
Lyu et al. | Automatic label-free immunoassay with high sensitivity for rapid detection of SARS-CoV-2 nucleocapsid protein based on chemiluminescent magnetic beads | |
CN107831314A (zh) | 一种n‑中端骨钙素化学发光检测试剂盒及其制备方法 | |
CN103063845A (zh) | 一种乙型肝炎病毒表面抗体的纳米磁微粒化学发光测定试剂盒及其制备方法和检测方法 | |
CN109669044A (zh) | 基于双色量子点联合检测saa和crp的荧光免疫吸附检测试剂盒及其制备方法 | |
CN108169486A (zh) | 一种测定鳞状上皮细胞癌抗原含量的试剂盒及其测试方法 | |
CN101514991A (zh) | 甲胎蛋白磁微粒化学发光免疫分析测定试剂盒及其制备方法 | |
CN103558381A (zh) | 检测人类艾滋病病毒抗体的免疫层析试纸及其制备方法 | |
CN103018445A (zh) | 糖类抗原50磁微粒化学发光免疫定量检测试剂盒及其制备方法 | |
CN107843734A (zh) | 一种性激素结合球蛋白的磁微粒化学发光检测试剂盒及制备方法 | |
CN103048453B (zh) | 一种糖类抗原ca19-9的纳米磁微粒化学发光测定试剂盒及其制备方法和检测方法 | |
CN103175963A (zh) | Tp抗体检测法及其检测试剂盒 | |
US11543413B2 (en) | Kit and method for quantitative detection of HBsAg | |
CN109239359A (zh) | β2-MG化学发光免疫分析测定试剂盒及其制备方法 | |
CN103048461A (zh) | 一种癌抗原ca15-3的纳米磁微粒化学发光测定试剂盒及其制备方法和检测方法 | |
JP2021038980A (ja) | Afp−l3測定方法及びafp−l3測定キット、並びに、これらに用いるブロック化標識レクチン | |
CN102621301B (zh) | 一种基于硝酸纤维素膜的蛋白芯片封闭液的制备方法 | |
CN103308677B (zh) | 一种雌二醇纳米磁微粒化学发光免疫定量检测试剂盒及其制备方法 | |
CN108008136A (zh) | 一种t淋巴细胞白血病病毒 (htlv) 抗体化学发光检测试剂盒及其制备方法 | |
CN105181956B (zh) | 基于金属离子特异响应的荧光检测法在免疫检测中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 102200, Beijing Changping District science and Technology Park, super Road, No. 37 Co-patentee after: Beijing Tongren Hospital, Capital Medical University Patentee after: Beijing Huizhong Medical Equipment Co., Ltd Co-patentee after: Liu Xiangdai Address before: 102200, Changping District Beijing science and Technology Park, super Road, No. 37, building 6, 5 Co-patentee before: Beijing Tongren Hospital, Capital Medical University Patentee before: Beijing Runnuosi Medical Science & Technology Co., Ltd. Co-patentee before: Liu Xiangdai |